[Adding an anti-leukotriene: results of the IMPACT study].
Lipworth
B
B
Ninewells University Hospital, Dundee.
D000085:Acetates / Q000008:administration & dosage; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D004983:Ethanolamines / Q000008:administration & dosage; D000068298:Fluticasone; D000068759:Formoterol Fumarate; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage*; D011804:Quinolines / Q000008:administration & dosage; D000068299:Salmeterol Xinafoate; D013440:Sulfides
D000085:Acetates; D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D001993:Bronchodilator Agents; D003521:Cyclopropanes; D003692:Delayed-Action Preparations; D004983:Ethanolamines; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; C093875:montelukast; D000420:Albuterol; D000068759:Formoterol Fumarate